The TCGA breast cancer cohort study corroborated that the expression of the ferroptosis‐related protein SLC3A2 is positively correlated with TYRO3 expression, and high TYRO3 expression is associated with resistance to PD‐1 inhibitors in breast cancer patients [36]. The gene discussed is TYRO3; the disease is breast carcinoma.